AlphAIalphai — Financial news for AI agents
benzinga.comJUL 313 min read$MMSI

These Analysts Increase Their Forecasts On Merit Medical Systems After Strong Q2 Results - Merit Medical

Merit Medical Systems Inc (NASDAQ:MMSI) posted better-than-expected earnings for the second quarter on Thursday. The company posted adjusted EPS of $1.19, beating market estimates of 96 cents per share. The company’s sales came in at $418.843 million versus expectations of $405.268 million. Merit Medical Systems raised its FY2026 adjusted EPS guidance from $4.01-$4.15 to $4.25-$4.35 and increased its sales forecast from $1.612 billion-$1.634 billion to $1.631 billion-$1.643 billion.

Original reporting
benzinga.com
Published Jul 31, 2026, 11:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 11:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$MMSI
Bullish
high confidence
Mentioned
$MMSI
Relevance
8/10
alphai data visualization · based on benzinga.com
Decision brief

The 30-second read

$MMSIBullishMed
01

Why it matters

The guidance raise is the key tradable input, likely prompting analysts to revise models and supporting momentum trading after the earnings print.

02

Market read

A same-day earnings beat plus explicit FY2026 guidance increases is a direct catalyst for estimate revisions and near-term positioning.

03

What to watch

The article does not provide segment performance, cash flow, or margin drivers, which are often what determine whether guidance raises are durable.

Relevance 8/10Novelty 8/10Timing: pre-market today after Q2 results and FY2026 guidance raise

Background

Merit Medical reported better-than-expected Q2 results and responded by increasing FY2026 adjusted EPS and sales guidance ranges.

Company-level read

Ticker impact

$MMSIBullishHigh confidence
Context

Merit Medical beat Q2 EPS and revenue, then raised FY2026 adjusted EPS guidance to $4.25-$4.35 and sales to $1.631B-$1.643B.

Expected impact

Likely continued upward bias versus prior consensus, though follow-through depends on how the market interprets the raised range.

Evidence & confidence

The article discloses a same-day earnings beat plus explicit FY2026 guidance increases, which are direct drivers of estimate revisions and valuation.

Market effects

Sector

Signals strength in medical device demand and/or execution for Merit Medical, which can modestly lift sentiment for medtech peers watching similar end-markets.

Regional

No specific regional demand or regulatory driver cited.

Global

No explicit global macro or international regulatory catalyst mentioned.

Counterpoint

What could challenge this read

Guidance raises may already be partially priced in after the Q2 beat, so upside could fade if investors focus on margins, backlog, or longer-cycle demand not discussed here.

Key entities

  • company
    Merit Medical Systems Inc

    NASDAQ-listed medical device company that beat Q2 estimates and raised FY2026 adjusted EPS and sales guidance.

  • analyst
    BTIG (Sam Eiber)

    Maintained Buy rating and raised price target from $100 to $105 after the earnings announcement.

  • analyst
    Needham (Mike Matson)

    Maintained Buy rating and raised price target from $90 to $101 after the earnings announcement.

Read at source← All news

Related articles

AUG 8
$MMSIMedAI 8/10

Merit Medical (MMSI) Q2 2026 Earnings Call Transcript

Merit Medical Systems (MMSI) reported Q2 2026 revenue of $418.8 million, up 10% GAAP, and non-GAAP EPS of $1.19. Non-GAAP operating margin was 22.6% and free cash flow $51.9 million. The company raised 2026 revenue guidance to $1.631B-$1.643B and non-GAAP EPS to $4.25-$4.35, and guided Q3 revenue to $408M-$413M.

fool.com6 min
JUL 30
$MMSIMedAI 8/10

Merit Medical Systems (NASDAQ:MMSI) Reports Bullish Q2 CY2026, Stock Soars

Medical device company Merit Medical Systems (NASDAQ: MMSI) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.5% year on year to $418.8 million. The company’s full-year revenue guidance of $1.64 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.19 per share was 24% above analysts’ consensus estimates. Is now the time to buy Merit Medical Systems? Find out by accessing our full research report, it’s free.

financialcontent.com4 min
JUL 30
$MMSIHigh

MERIT MEDICAL SYSTEMS INC (MMSI): Results of Operations and Financial Condition

MERIT MEDICAL SYSTEMS INC (MMSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mmsi-20260730xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ ​ ​ ​ ​ ​ ​ Contacts: ​ ​ ​ ​ PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare ​ ​ +1-801-432-2864 +1-443-213-0509 ​ ​ sarah.comstock@merit.com mike.piccinino@i

SEC EDGAR 8-K6 min
AUG 8
$SHOPMedAI 8/10

Shopify Was Supposed to Be an AI Casualty. Its AI-Referred Traffic Just Tripled.

Shopify (SHOP) reported Q2 results, citing AI-referred traffic to merchants’ storefronts that tripled year over year and orders that began with AI search also tripled. New buyers from AI channels placed orders at nearly twice the rate of other channels. Revenue rose 34% to $3.6B, GMV reached $115.6B, operating income rose 68% to $488M, and free cash flow was $654M.

yahoo.com6 min
AUG 8
$GPRKMed

Geopark Q2 Earnings Call Highlights

Geopark (NYSE:GPRK) reported Q2 earnings call updates. It plans $40m to $50m of Vaca Muerta investment in 2H 2026 after $55m in 1H, with 70% to 80% in Q3. Full-year lifting costs are guided at $17 to $19/bbl. Cash rose to $316m, net leverage fell to 1.2x EBITDA, and a $0.023/share quarterly dividend was declared.

yahoo.com6 min